The role of complex combination therapy in the treatment of refractory bipolar illness

CNS Spectrums

Volumn 3, Issue 5, 1998, Pages 66-86

  Robert, M ^a   Frye, Mark A ^a   Leverich, Gabriele S ^a   Denicoff, Kirk D ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CARBAMAZEPINE; DIHYDROPYRIDINE DERIVATIVE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; NIMODIPINE; TOPIRAMATE;

ADAPTATION; ALOPECIA; AMNESIA; DIABETES INSIPIDUS; DRUG EFFECT; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; HYPERCORTISOLISM; MANIC DEPRESSIVE PSYCHOSIS; PRIORITY JOURNAL; PROPHYLAXIS; REMISSION; REVIEW; SENSITIZATION; THROMBOCYTOPENIA; VERTIGO; WEIGHT GAIN;

EID: 0032437687     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900031175     Document Type: Review

References (81)

1. Kraepelin E. Manic-Depressire Insanity and Paranoia. Barclay UM, Irans; Roherton CM, ed. Edinburgh, Scotland: ESLivingstone;1921.
2. Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry. 1992;i49:999-1010.
3. Post RM, Weiss SRB. A speculative model of affective illness cyclicity lused on patterns of drug tolerance observed in amygdala-kindled seizures. Mol Neumbiol. 1996;13:33-60.
4. Marangell LB, George MS, Callahan AM, et al. Effects of intrathecal protirelin (thyrotropin-releasing homione) in refractory depressed patients. Arch Gen Psychiatry. 1997;51:214-222.
5. Callahan AM, Frye MA, Marangell LB, et al. Comparative antidepressant effects of intravenous and intrathecal thyrotropinreleasing hormone: confounding effects of tolerance and implications for tlierapeutics. Biol Psychiatry. 1997:41561-272.
6. Prange M Jr, Lara PP, Wilson 1C, Alllop LB, Breese GR. Effects of thyrotropin-releasing honnone in depression, innerJ. 1972:11:999-1002.
7. Post RM, Weiss SRB. Endogenous hiochemiral almonnalities in affective illness: therapeutic vs pathogenic. Bid Psychiatry. 1992:32:469-481.
8. Post RM, Leverich GS, Pazzaglia PJ, et al. Lithium tolerance arid discontinuation as pathways to refractoriness. In: Birch ISJ, Padgham C, Hughes MS, eds. lithium in Medicine and Biology. Lancashire, UK: Marius Press; 1993:71-81.
9. Post RM, Leverich GS, Rosoff AS, Aluliuler I.L Carhamazcpine proplnlaxis in refractor)- affective disorders: a focus on long-term follow-up. J Clin Psychopharmacol. 1990;10:318-327.
10. Weiss SU, Clark XI, Rosen JB, Smith MA. Post RM. Contingent tolerance to the anliconvulsant effects of carbamazepine: relationship to loss of endogenous adaptive mechanisms. Brain Res Rei: 1995:20:305-325.
11. O'Connell RA, .Mayo JA, Flatow I. Cuthlieitson B. O'Brien BE. Outcome of hipolar disorder on long-term treatment with lithium. Rr J Psychiatry: 1991:159:123-129.
12. Sarantidis D, Waters B. Predictors of lithium prophylaxis effectiveness. Prog- Neuropsychopliarmacd. 1981; 5:507-510.
13. Denicoff KD, Smith-Jackson EE, Disney ER, Ali SO, Leverich GS, Post RX1. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in hipolar disorder, y Clin Psychiatry. 1997;58:470478.
14. Post RM, Ketter TA, Pazzaglia PJ, et al. Rational polypharmacy in the bipolar affective disorders. Epilepsy Res. 1996;(supplll):153-180.
15. Gelei J>erg AJ, Kane JM, Keller X1B, et al. Comparison of standard and low serum levels of lithium for maintenance treatment ofbipolardisoider.ATn£ V l989-,321:1489-1493.
16. Koukopoulos A, Reginaldi D, Xlinnai G, Serra G, Pani L. Johnson Fi\. Tlie long tenu prophylaxis of affective disorders. Adv Biofhem Psychopharmacol. 1995;49:127-147.
17. Xlarkar HR, Mander AJ. Efficacy of lithium prophylaxis in clinical practice. Br J Psychiatry. 1909;15:496-500.
18. Vestergaard P.Treatment and prevention ofmania: a Scandinavian perspective. Neuropsychopharmacol. 1992;7:249-260.
19. Gitlin XIJ, Swendsen J, Heller.TU Ilammen C. Relapse and impairment in bipolar disorder. Am J Psychiatry. 1995;152:1635-1610.
20. Kravitz HM, Fawcell J. Carlamazepine in the treatment of affective disorders. Med Sci Res. 1987;15:l-8.
21. Schaff XIR, Fawcett J, Zajccka JM. Divalproex sodium in the treatment of refractory affective disorders. J Clin Psychiatry. 1993;51:380-381.
22. Post UM, Ketter TA, Denicoff K. et al. The place of anticonvulsant therapy in bipolar illness. Psychopharmacology (Bed). 1996;128:115-l29.
23. Post RM, Denicoff KD, Frye MA. Leverich GS. Re-evaluating carbamazepine prophylaxis in bipolar disorder. Br ] Psychiatry. 1997:170:202-201.
24. Frye X1A. The increasing use of polypharmaey for refractory mood disorders: twenty-five years of study. APA Arch Research Program and Abstracts. 1996:151-152. Abstract.
25. Post R.M, Ulule TW, Roy-Byrne PP, Joffe RT. Antidepressant effects of carbamazepine. Int J Psychiatry. 1986;143:29-3I.
26. Post RXI, Uhde TW, Roy-Byme PP, Joffe RT. Con-elates of anlimanic response to carbamazepine. Psychiatry Res. 1987:21:71-83.
27. Kramlinger KG, Post RM. Tlie addition of lithium carbonate to carbamazepine: antidepressanl efficacy in treatmentresistant depression Arch Gen Psychiatry. 1989;46:791-800.
28. Seniyak MJ, Woods SW. Chronic neuroleplic use in manicdepressive illness. Psychophannacol Bull. 199329:375-381.
29. Hunt N, Silverstone T. Tanlive dyskinesia in bipolar affective disoixler: a catchment area study. Inl Clin Psycliopharmacol. 1991:6:45-50.
30. Jeste DV. Wyalt RJ. Therapeutic strategies against tardive dyskinesia. Arch Gen Psychiatry. 1982:39:803-816.
31. Glenthoj 15, Hemmingseii Ii, Allcrup I, Bolwig TG. Intermittent versus continuous neuroleptic treatment in a rat model Eur J Pharmacol. 1990:190:275-286.
32. Calabrese JR. Kimmel SE. Woyshville MJ. el al. Clnzapinc for treatment-refractory mania. Am J Psychiatry: 1996:153:759-761.
33. McElroy SL Dessain EC. Pope HG Jr. el a!. Cloznpine in the treatmenl of psjchotic mood disorders, schizreiffective disorder, and schizophrenia. J Clin Psychidtn: 1991:52:111-114.
34. Suppes T. McElroy SL Gilkrt J, Dessain EC. Cole JO. Clozapine in the treatment of dysphoric mania. Biol Psychiatry. 1992:32:270-280.
35. Kenvin R, Tay lor D. New anlipsychotics. A review of llieir current status and clinical potential. CAS Drugs. 1996:6:71-82.
36. Keck I'E Jr. Wilson DR. Slrakowski S.M, et al. Clinical predictors of acute risperidone response in schizophrenia, schizoaffecliie disorder, and psychotic mood disorders. J Clin Psychiatry. 1995;56:166-170.
37. Tolien M, Zarate CA Jr, Centorrino F, 1 legally JI, Froeschl M, Zarate SB. Risperidone in the treatment of mania. J Clin Psychiatry. 1996:57:219-253.
38. Gross G, Xin X, Gastpar M. Trimipramine: phannacological réévaluation and comparison with clozapine. Neuropharmacology: 1991:30:1159-1166.
39. Eikmeier G, Berger M, Lodemann E, Muszynski K, Kaumeier S, Gastjiar XI. Trimipmmine-an atypical neuroleptic? Int Clin Psychopharmacol. 1991:6:1-17-153.
40. Pazzaglia PJ, Post RM, Kelter TA, George MS, Xlarangell LB. Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation Psychiatry1993;49A57-272.
41. Pazzaglia PJ, Post RM. Kelter TA, el al. Nimodipine nionotherapy and carbamazepine augmenlalion in [xitienls with refractory recurrent affective illness. J Clin Psychopharmacol. In press.
42. Dulxnsky SL Calcium channel antagonists as novel agents for manic-depressive disorder. In: Schatzlierg AF, Nemeroff CB, eds. Textbook of Psychopharmacology. Washington, DC: American Psychiatric Press: 1995:377-388.
43. Pazzaglia PJ, George MS, Pest RM, Rubinow DR, Davis C. Nimodipine increases CSF somaloslatin in affectively ill patients. Neuroflsychophamacol. 1995;13:75-83.
44. Ban TA, Morey I, Aguglia E, et al. Nimodipine in the treatment of old age dementias. Prog i\europsychopharmacol Biol Psychialr): 1990,14:525-551.
45. Calabrese JR, Bern den CL, MeElroy SL, et al. Lamolrigine in bipolar disorder preliminary data Syllabus and Proceedings Summary of the 150th American Psychiatric Association Meeting, May 17-22,1997. Abstract No 33B.
46. Beriant JL ADHD and bipolar disonler as predictors of clinical response to lamotrigiiie. Proceedings of the Second International Conference on Bipolar Disonler, 1997:7. Abstract.
47. Ferner IN, Potkins D, Eccleston D. Lamotrigine treatment in rapid cycling bipolar disorder (BPD): clinical and biological correlates. Proceedings of the Second International Conference on Bipolar Disorder. 1997;15. Abstract.
48. Hoopes S, Snow M. Clinical effectiveness of lamotrigine in affective disorders. Proceedings of die Second International Conference on Bipolar Disorder. 1997:26. Abstract.
49. Frye MA, Ketter TA, Kimbrell TA, et al. Galxipentin and lamotrigine monotherapy in mood disorder. S)llabus and Proceedings Summary of the 150th American Psycliiatric Association Meeting. May 17-22,1997. Abstract No. 33C.
50. Messenheimer JA. Lamotrigine. Epilepsia. 1995;36 (suppl 2)587-594.
51. Sachs B, Ronnau AC, von Schmiedeberg S, Ruzicka T, Gleichmann E, Schuppe HC. Lamotrigine-induced StevensJohnson syndrome: demonstration of specific lymphocyte reactivity in vitro. Dermatology: 1997;195:60-6l.
52. Sterker M, Berrouschot J, Schneider D. Fatal course of toxic epidermal necrolysis under treatment with lamotrigine. Int J Clin Pharmacol Ther. 1995;33:595-597.
53. Kocsis JD, Mattson Rl 1. GABA levels in die brain: a target for new antiepileptic drugs. Tlie Neurvscientist. 1996Ä326-334.
54. Young LT, Robb JC, Patelis-Siotis I, MacDonald C, Joffe RT. Acute treatment of bipolar depression with gabapentin. Biol Psychiatry. 1997;42:851-853.
55. Dimond KR, Pande AC, Lamoreaux L, Pierce MW. Effect of gabapentin (Neurotonin) on mood and well-being in patients with epilepsy. Prog Neuropsychopharmacol Biol Psychiatry. 1999;20:407417.
56. Marcotte DB, Fogleman L, Wolfe N, et al. Gabapentin: an effective therapy for patients with bipolar affective disorder. APA New Research Program and Abstracts. 1997;138. Abstract NR261.
57. Joffe RT, Singer W, Levitt AJ, MacDonald C. A placebo-controlled comparison of lidiium and triiodolhyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry: 1993;50:387-393.
58. Cooke RG, Joffe RT, Levitt AJ. T3 augmentation of antidepressant treatment in T4-repIaced thyroid patients. J Clin Psychiatry: 1992;53:16-18.
59. Stancer HC, Persad E. Treatment of intractable rapid-cycling manic-depressive disorder with levothyroxine. Arch Gen Psychiatry. 1982:39:311-312.
60. Whybrow PC. The therapeutic use of triiodothyronine and high dose thyroxine in psychiatric disorder. /lc(a Med Austriaca. 1994:21:47-52.
61. Baumgartner A, Bauer M, Hellweg R. Treatment of intractable non-rapid cycling bipolar affective disorder with high-dose thyroxine: an open clinical trial. i\'europs)rhophamwcol. 1991;10:183-189.
62. Fiye MA, Denicofl" KD, Luckenbaugh DA, et al. Thyroid polentiation in affective illness. APA New Research Program and Abstracts. 1997. Abstract NR425.
63. Bauer MS, Why brow PC. Rapid cycling bipolar affective disorder. II: treatment of refractor)- rapid cycling with high-dose levothyroxine: a preliminary study. Arch Gen Psychiatry; 1990;47:435-HO.
64. Bauer M, Hellweg R, Baumgartner A. Adjunctive treatment with high-dose thyroxine in refractory depression. APA New Research Program and Abstracts. 19%;156. Abstract NR330.
65. Perucca E. A pliarmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol Res. 1997;5241-2,%.
66. Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia. 1996;37(suppl 2):S18-S22.
67. Ozaki N, Chuang DM. Litliium increases transcription factor binding lo AP-1 and cyclic AMP-responsive element in cultured neurons and rat brain. J Neurochem. 1997;69:2336-2314.
68. Chen G, Yuan P, Hawver DB, Potter WZ, Manji HK. Increase in AP-1 transcription factor DNA binding activity by valproic acid. Neuropsychopharmacology. 1997;16:238-245.
69. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry: 1997-1:597-606.
70. Smitli MA, Makino S, Allemus M, et al. Stress and antidepressants differentially regulate neurolrophin 3 mRNA expression in the locus coeruleus. Proc Natl Acad Sci USA. 1995;92:8788-8792.
71. Siuciak JA, Lewis DR, Wegand SJ, Lindsay RM. Antidepressant-like effect of brain-derived neurotrophic factor (BDN'F). Pharmacol Kochern Behai: 1997;56:131-137.
72. Baastrup PC, Schou M. Litliium as a prophylactic agent: its effect against recurrent depressions and manic-depressive psychosis. Arch Gen Psychiatry. 1967;16:162-172.
73. Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation pf lithium treatment in bipolar disorder. Arch Gen Psychiatry' 1991;48:1082-1008.
74. Faedda GL, Tondo L, Baldessarini RJ, Suppes T, Tohen M. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry. 1993;50:448455.
75. Post RM, Leverich GS, Altshuler L, Mikalauskas K. Lithium discontinuation-induced refractoriness: preliminar)1 observations. Am J Psychiatry. 1992;149:1727-1729.
76. Brodie MJ, Yuen AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res. 199726:423-432.
77. Ketter TA, Kimbrell TA, George MS, et al. Baseline hypermetabolism may predict carbamazepine response, and hypometabolism nimodipine response in mood disorders. Abstracts of the XXth CLN'P Congress. 1996:10.
78. Frye MA, Pazzaglia PJ, Luckenbaugh D, el al. Baseline CSF somatostatin predictive of nimodipine treatment response. Biol Psychiatry: 1997;41:33S. Abstract.
79. George MS, Wassermann EM, Williams WA, et al. Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. NeuroReport. 1995;6:1853-1856.
80. George MS, Wassermann EM, Kimbrell TA, et al. Mood improvement following daily left prefrontal repetitive Iranscranial magnetic stimulation in patients with depression: a placebo-controlled crossover trial. Am J Psychiatry. 1997;151:1752-1756.
81. Pascual-Leone A, Rubio B, Pallardo F, Catala MD. Rapidrate transcnmial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet. 1996;348:233-237.